Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
The use of PCV21 may be cost-effective in some populations, depending on the prevalence of IPD serotypes covered by PCV20 and PCV21.
Authors
- Austin Nam (ORCID: https://orcid.org/0000-0003-0714-8385)
- Alison E. Simmons (ORCID: https://orcid.org/0000-0001-8780-9467)
- Alyssa Golden (ORCID: https://orcid.org/0000-0002-1788-1794)
- Beate Sander (ORCID: https://orcid.org/0000-0003-2128-9133)
- Gebremedhin Beedemariam Gebretekle (ORCID: https://orcid.org/0000-0002-2485-505X)
- Matthew Tunis (ORCID: https://orcid.org/0000-0003-2092-9143)
- Marina I. Salvadori (ORCID: https://orcid.org/0000-0001-5371-6510)
- Raphael Ximenes (ORCID: https://orcid.org/0000-0003-2536-951X)
- Kyla J. Hildebrand (ORCID: https://orcid.org/0000-0003-3825-8202)
- Ashleigh R. Tuite (ORCID: https://orcid.org/0000-0002-4373-9337)
- Eva Wong (ORCID: https://orcid.org/0000-0001-8349-3733)
Institutions
- Public Health Agency of Canada (CA)
- Toronto Rehabilitation Institute (CA)
- McGill University Health Centre (CA)
- Public Health Ontario (CA)
- Institute for Work & Health (CA)
- BC Children's Hospital (CA)
Publication Details
- Journal
- Vaccine
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1016/j.vaccine.2025.126985
- Citations
- 8
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 10.83